From GlobeNewswire: 2025-03-13 07:30:00

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has made significant progress in 2024, particularly with QRX003 for Netherton Syndrome. The company’s FDA-cleared whole-body clinical study will provide robust safety and efficacy data. Recent patent filings for novel topical rapamycin formulations are expanding the pipeline to include rare dermatological diseases.

Recent achievements include filing patent applications for novel topical rapamycin formulations targeting various rare diseases. Positive whole-body clinical data from a pediatric Netherton Syndrome study showed remarkable improvement in just two weeks, with no adverse events reported. Quoin also launched an awareness campaign for Netherton Syndrome and released clinical evidence supporting QRX003’s effectiveness.

In the fourth quarter of 2024, Quoin completed a successful $6.8 million public offering to support ongoing clinical development. FDA clearance was received for a groundbreaking whole-body clinical study for QRX003, led by Dr. Amy Paller at Northwestern University. Positive interim data from ongoing Netherton Syndrome studies showed significant clinical responses.

As of December 31, 2024, Quoin had approximately $14.1 million in cash, cash equivalents, and marketable securities. The net loss for the quarter ended December 31, 2024, was approximately $2.3 million. Quoin Pharmaceuticals is focused on developing and commercializing therapeutic products for rare and orphan diseases, with an innovative pipeline targeting various indications.



Read more at GlobeNewswire:: Quoin Pharmaceuticals Provides Corporate Update and Reports